0
0
A growing body of research highlights the critical role of cardiometabolic progression in predicting the risk of hypertension and diabetes among individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), the newly redefined clinical group previously classified under non-alcoholic fatty liver disease (NAFLD). Recent cohort studies and systematic analyses shed light on how closely tied cardiometabolic risk is to future adverse health events for this vulnerable population.
Cardiometabolic Indices as Predictors
Large-scale cohort studies confirm that elevated cardiometabolic indices—such as the cardiometabolic index (CMI), atherogenic index of plasma (AIP), and triglyceride-glucose (TyG)—dramatically increase the likelihood of developing MASLD and its progression to more severe complications, including liver fibrosis and cardiometabolic diseases1. People falling in the upper quartiles of these cardiometabolic indices showed up to a six-fold higher risk of MASLD onset compared to those in the lowest quartile. Moreover, subgroup analyses revealed these associations persist across gender and in individuals without other risk factors like obesity or hypertension.
Compounding Risks: Hypertension and Diabetes
Patients with MASLD are much more likely to have or develop hypertension and type 2 diabetes mellitus, which are the leading drivers of adverse outcomes and mortality in this group. The aggregate burden of cardiometabolic dysfunction (blood pressure, glucose, and lipid abnormalities) correlates with sharply reduced survival and heightened cardiovascular-specific mortality. Studies indicate that adults with MASLD who accumulate multiple metabolic risk factors face a three- to eightfold increased risk of death from all causes, particularly cardiovascular events. Among the cluster of cardiometabolic risks, blood glucose and blood pressure abnormalities are predominant, underscoring the necessity of close monitoring and management of these parameters in MASLD patients.
Pathogenic Mechanisms and Prognosis
Research details several key mechanisms underpinning the link between cardiometabolic dysfunction and MASLD progression, including inflammation, oxidative stress, endothelial dysfunction, and insulin resistance. These mechanisms not only accelerate the advancement of liver disease but also drive cardiovascular events. As such, clinicians and patients are urged to view MASLD not just as a liver-centric disease but as a multisystem disorder requiring comprehensive cardiometabolic risk assessment and intervention.
Clinical Implications
Experts suggest that, beyond traditional liver-focused therapies, intensified clinical surveillance targeting cardiometabolic risk factors—especially hypertension and diabetes—is crucial for MASLD populations. Early diagnosis and personalized management based on the patient’s cardiometabolic profile may help mitigate risks and improve long-term outcomes.
Disclaimer:
This news article is intended for informational purposes only and does not substitute professional medical advice, diagnosis, or treatment. Individuals should consult qualified healthcare professionals for any questions regarding their health conditions or management strategies.
